US Bancorp DE Sells 651 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

US Bancorp DE reduced its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 30.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,465 shares of the company’s stock after selling 651 shares during the quarter. US Bancorp DE’s holdings in Kymera Therapeutics were worth $69,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD boosted its position in shares of Kymera Therapeutics by 18.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock worth $254,548,000 after purchasing an additional 996,300 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Kymera Therapeutics by 19.2% during the first quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock worth $191,635,000 after buying an additional 769,486 shares during the last quarter. Artal Group S.A. grew its position in shares of Kymera Therapeutics by 19.6% during the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock worth $121,691,000 after buying an additional 496,400 shares during the period. Driehaus Capital Management LLC bought a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at about $6,669,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at approximately $4,271,000.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock opened at $41.96 on Monday. The firm has a market cap of $2.72 billion, a PE ratio of -17.93 and a beta of 2.21. The business’s 50 day simple moving average is $47.17 and its 200 day simple moving average is $41.72. Kymera Therapeutics, Inc. has a 52-week low of $16.94 and a 52-week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. During the same quarter in the previous year, the firm posted ($0.90) earnings per share. The firm’s revenue for the quarter was down 20.9% on a year-over-year basis. As a group, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KYMR. Truist Financial restated a “buy” rating and set a $53.00 price objective (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Wells Fargo & Company boosted their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Oppenheimer raised their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, September 27th. Guggenheim increased their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Monday, September 9th. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $51.21.

Insider Transactions at Kymera Therapeutics

In other news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. Company insiders own 15.82% of the company’s stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.